ABIVAX’s Novel Approach to Treat HIV Demonstrates Safety and Preliminary Anti-viral Activity in Phase IIa

Paris, France, February 25th, 2016 – ABIVAX (Euronext Paris: FR0012333284 – ABVX), an emerging leader in developing and commercializing anti-viral drugs and therapeutic vaccines for diseases like HIV/AIDS and chronic hepatitis B (CHB), today presented data from the Company’s Phase IIa study demonstrating the safety and potent viral reduction capacity of ABX464 in treatment-naïve HIV positive patients. Data were presented by Dr. Jean-Marc Steens, M.D., Chief Medical Officer at ABIVAX, summarizing the findings published in an abstract entitled, “Early Evidence of Antiviral Activity and Safety of ABX464 in HIV Treatment Naïve Patients, at the Conference for Retroviruses and Opportunistic Infections (CROI) in Boston, USA. ABX464 is an orally available therapeutic that blocks HIV replication through an entirely novel mechanism, i.e. the modulation of the biogenesis of viral RNA, and acts by targeting the Rev protein. ABIVAX believes that ABX464 could address the urgent need for long-term control of HIV rebound following the cessation of treatment.

Press contacts

Caroline Carmagnol 

abivax@alizerp.com

+ 33 6 64 18 99 59 or
+ 33 1 44 54 36 65

 Standard: +33 1 53 83 08 41